Novo Nordisk Expands Semaglutide Studies for Alcohol Use Disorder and Obesity | NEREUS™ (tradipitant): A New Era in Motion Sickness Treatment | TrumpRx Expands with AbbVie and Genentech, Raising Pricing Questions | J&J Wins Approval for First-of-its-Kind Psoriasis Pill Icotyde | FDA Warns Novo Nordisk of Unreported GLP-1 Side Effects | Hims & Hers Announces $49 Wegovy Copy, Novo Nordisk and Eli Lilly Tumble | Tylenol Maker Disputes FDA Proposal Linking Use During Pregnancy to Autism | VOQUEZNA® Receives 10-Year Exclusivity Extension from FDA | Novo Nordisk Expands Semaglutide Studies for Alcohol Use Disorder and Obesity | NEREUS™ (tradipitant): A New Era in Motion Sickness Treatment | TrumpRx Expands with AbbVie and Genentech, Raising Pricing Questions | J&J Wins Approval for First-of-its-Kind Psoriasis Pill Icotyde | FDA Warns Novo Nordisk of Unreported GLP-1 Side Effects | Hims & Hers Announces $49 Wegovy Copy, Novo Nordisk and Eli Lilly Tumble | Tylenol Maker Disputes FDA Proposal Linking Use During Pregnancy to Autism | VOQUEZNA® Receives 10-Year Exclusivity Extension from FDA
Novo Nordisk is broadening its research into semaglutide, originally developed for diabetes and obesity, to explore its potential in treating alcohol use disorder. Simultaneously, the company is advancing its pipeline with LX9851, an oral d...
Image via The Providence Journal
Can GLP-1s quiet drug cravings? How a RI program is finding out
Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years
Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032
